Investment Summary

Signet Healthcare Partners Invests In Juno Pharmaceuticals

On February 24, 2022, growth capital firm Signet Healthcare Partners invested in life science company Juno Pharmaceuticals

Investment Highlights
  • This is Signet Healthcare Partners’ 10th transaction in the Life Science sector.
  • This is Signet Healthcare Partners’ 2nd transaction in Canada.
  • This is Signet Healthcare Partners’ 1st transaction in Ontario.

Investment Summary
Date 2022-02-24
Target Juno Pharmaceuticals
Sector Life Science
Investor(s) Signet Healthcare Partners
Deal Type Growth Capital
Advisor(s) Aird & Berlis (Legal)

Target

Juno Pharmaceuticals

Mississauga, Ontario, Canada
Juno Pharmaceuticals is a specialty pharmaceutical company with a focus on injectable generic drugs sold through hospital channels. Juno Pharmaceuticals was founded in 2012 and is based in Mississauga, Ontario.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Signet Healthcare Partners

Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1998
PE ASSETS 600M USD
Size Middle-Market
Type Sector Focused
DESCRIPTION

Signet Healthcare Partners is a growth capital firm focused on the healthcare sector. Specific areas of interest include specialty pharmaceuticals, pharmaceutical services, medical devices, and diagnostics. Signet will consider opportunities throughout North America and Europe and looks to commit $10 to $50 million per transaction. Signet Healthcare Partners was established in 1998 and is headquartered in New York, New York.

DEAL STATS #
Overall 12 of 15
Sector (Life Science) 10 of 12
Type (Growth Capital) 7 of 10
State (Ontario) 1 of 1
Country (Canada) 2 of 2
Year (2022) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-08 Ascendia Pharmaceuticals

North Brunswick, New Jersey, United States

Ascendia Pharmaceuticals is a specialty CDMO dedicated to developing and manufacturing enhanced formulations for pre-clinical and clinical stage drug candidates and marketed drug products. Ascendia specializes in improving the solubility and bioavailability of poorly water-soluble drugs using its suite of nanotechnology platforms. Ascendia formulates products for injectable, oral, and topical routes of administration. The company has three technology platforms - EmulSol® for producing nano-emulsions, AmorSol® for creating amorphous solid dispersions, and NanoSol® for formulating nano-particles. Ascendia Pharmaceuticals was founded in 2012 and is based in North Brunswick, New Jersey.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-10-24 Laxai

Hyderabad, India

Laxai offers contract research, development, and manufacturing solutions to pharmaceutical and specialty chemical companies globally. Laxai has collaborated with pharmaceutical companies across the value chain and partnered on multiple medicinal chemistry, integrated drug discovery, CMC Programs, and scale-up of custom-made specialty fine chemicals. Laxai is based in Hyderabad, India.

Buy -
Mergr

Product

Company

Legal